Howe & Rusling’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-273
Closed 1054
2020
Q4
$0 Buy
273
+198
+264% +$422 ﹤0.01% 1029
2020
Q3
$0 Sell
75
-250
-77% -$714 ﹤0.01% 894
2020
Q2
$1K Hold
325
﹤0.01% 784
2020
Q1
$1K Hold
325
﹤0.01% 769
2019
Q4
$1K Buy
+325
New +$845 ﹤0.01% 819

Other funds holding BMY.RT

Howe & Rusling's BMY.RT Position: Q1 2021 in Review

Howe & Rusling sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 273 shares.

Howe & Rusling first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Howe & Rusling reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Howe & Rusling sold 273 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Howe & Rusling first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Howe & Rusling's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Howe & Rusling's 13F filing for Q1 2021, filed 13 May 2021.